Search
Didn't find any results in this catalog!
But we have some results in other catalogs.displaying 1000 best results Help
Search results for: OPIOID GROWTH FACTOR
-
Opioid Growth Factor and its Derivatives as Potential Non-toxic Multifunctional Anticancer and Analgesic Compounds
PublicationIn this paper, we review the structure-activity relationship of OGF and its analogues. We highlight also OGF derivatives with analgesic, immunomodulatory activity and the ability to penetrate the blood-brain barrier and may be used as safe agents enhancing chemotherapy efficacy and improving quality of life in cancer patients. The reviewed papers indicate that Met-enkephalin and its analogues are interesting candidates for the...
-
CRH functions as a growth factor/cytokine in the skin
Publication -
Vascular endothelial growth factor (VEGF)-C - a potent risk factor in children diagnosed with stadium 4 neuroblastoma.
Publication -
Vascular endothelial growth factor C—a potent risk factor in childhood acute lymphoblastic leukaemia: an immunocytochemical approach
Publication -
Insulin-like growth factor type 2 is better than insulin-like growth factor type 1 a survival marker in patients after acute decompensation of heart failure
PublicationIntroduction:A decreased IGF-1 has been found in heart failure (HF). There are no reports assessing IGF-2 in HF, although in vitro study has shown, that IGF-2 stimulates cardiomyocyte proliferation more than IGF-1. The study aim was to compare the IGF-1 and IGF-2 concentration depending on HF exacerbation and annual survival.Material and methods:Among 75 patients hospitalized...
-
Anticancer imidazoacridinone C-1311 inhibits hypoxia-inducible factor-1α (HIF-1α), vascular endothelial growth factor (VEGF) and angiogenesis
PublicationAntitumor imidazoacridinone C-1311 is a DNA-reactive topoisomerase II and FLT3 receptor tyrosine kinase inhibitor. Here, we demonstrate the mechanism of C-1311 inhibitory action on novel targets: hypoxia-inducible factor-1α (HIF-1α), vascular-endothelial growth factor (VEGF), and angiogenesis. In a cell-free system, C-1311 prevented HIF-1α binding to an oligonucleotide encompassing a canonical hypoxia-responsive element (HRE),...
-
CD105 and placental growth factor – Potent prognostic factors in childhood acute lymphoblastic leukaemia
Publication -
Triazolopeptides Inhibiting the Interaction between Neuropilin-1 and Vascular Endothelial Growth Factor-165
Publication -
DNA-reactive anticancer imidazoacridinone C-1311 is a new inhibitor of hypoxia-inducible factor 1 alpha, vascular endothelial growth factor and tumor angiogenesis
PublicationHypoxia-inducible factor 1 (HIF-1) plays a critical role for tumor adaptation to hypoxia and promotes angiogenesis. Antitumor imidazoacridinone C-1311 is a DNA reactive topoisomerase II and FLT3 receptor tyrosine kinase inhibitor selected for phase II clinical trials for breast cancer. Here, we demonstrate the new mechanism of C-1311 action involving HIF-1a, vascular endothelial growth factor (VEGF) and angiogenesis as additional...
-
The influence of a synthetic growth hormone‐releasing hormone analogue G11 and opioid peptide biphalin on selected fibroblasts parameters relevant to wound healing
Publication